Collegium Pharmaceutical downgraded by H.C. Wainwright
$COLL
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded Collegium Pharmaceutical from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2024 | $47.00 | Neutral → Buy | H.C. Wainwright |
| 6/7/2024 | $41.00 → $44.00 | Hold → Buy | Jefferies |
| 5/10/2024 | Buy → Hold | Needham | |
| 5/10/2024 | $39.00 | Overweight → Neutral | Piper Sandler |
| 1/4/2024 | $30.00 → $37.00 | Buy → Hold | Jefferies |
| 8/25/2023 | $35.00 → $36.00 | Buy | Needham |
| 5/2/2023 | $30.00 | Buy | Jefferies |
| 8/8/2022 | Buy → Neutral | H.C. Wainwright |
Jefferies analyst Glen Santangelo upgrades Collegium Pharmaceutical (NASDAQ:COLL) from Hold to Buy and raises the price target from $41 to $44.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $115 million remaining under the program.
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q3 2024 Earnings Call." An audio webcast will
– Adds Commercial Product Jornay PM®, Establishing Collegium's Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million – STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has completed the acquisition of Ironshore Therapeutics Inc., a privately held company that markets and distributes Jornay PM (methy
STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Monday, September 9, 2024, at 12:30 p.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com A replay of the w
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
10-Q - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that effective May 24, 2024, Joe Ciaffoni will step down as President and Chief Executive Officer (CEO) of the Company. Mr. Ciaffoni will serve as a member of the Board of Directors of the Company until the
STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. "Collegium is delighted to welcome Neil to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Neil's track record of successful leadership and industry experience will be tremendously valuable for the Company. We are confident that Collegium will benefit from his insights, and we look forward to Neil's meaningful contributions to our Board of Directors." "This is a very important and exci
– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta® Franchise and Adjusted EBITDA 2021 Guidance Range Raised – – Colleen Tupper Appointed as Next CFO; Paul Brannelly will be Leaving the Company to Pursue Other Opportunities – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update. The company also announced the appointme
STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q3 2024 Earnings Call." An audio webcast will
– Adds Commercial Product Jornay PM®, Establishing Collegium's Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million – STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has completed the acquisition of Ironshore Therapeutics Inc., a privately held company that markets and distributes Jornay PM (methy
– Generated Q2'24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2'24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2'24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironshore Therapeutics in Q3'24, Adding Commercial Product Jornay PM® to Portfolio and Establishing Presence in Neurology (ADHD) – – Reaffirmed Full-Year 2024 Guidance for the Current Business – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00
Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously
Needham downgraded Collegium Pharmaceutical from Buy to Hold